Common variable immunodeficiency: Difference between revisions

From IDWiki
Content deleted Content added
No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 2: Line 2:


*Characterized by decreased IgG immunoglobulins, with or without decreases in IgA and IgM, and decreased response to vaccination
*Characterized by decreased IgG immunoglobulins, with or without decreases in IgA and IgM, and decreased response to vaccination
*Must exclude other causes of hypogammaglobulinemia
*Must exclude other causes of [[hypogammaglobulinemia]]

=== Classification ===

*


===Epidemiology===
===Epidemiology===
Line 12: Line 8:
*Affects up to 1 in 25,000 people
*Affects up to 1 in 25,000 people


== Clinical Manifestations ==
==Clinical Manifestations==


* Wide spectrum of manifestations
*Wide spectrum of manifestations
* Most common presentation is recurrent sinopulmonary infections
*Most common presentation is recurrent sinopulmonary infections
** Especially [[Streptococcus pneumoniae]], [[Haemophilus influenzae]], and [[Mycoplasma species]]
**Especially [[Streptococcus pneumoniae]] and [[Haemophilus influenzae]]
**Severe or chronic [[Mycoplasma species|Mycoplasma]] infections
** [[Empyema]], [[bacteremia]], [[meningitis]], and [[osteomyelitis]]
**Severe or chronic [[Enterovirus]] infections, including meningitis
* Can eventually develop chronic lung disease including obstruction, restriction, and bronchiectasis
**[[Empyema]], [[bacteremia]], [[meningitis]], and [[osteomyelitis]]
* Diarrhea is common (21 to 57%)
*Can eventually develop chronic lung disease including obstruction, restriction, and bronchiectasis
** [[Giardia lamblia]] is the most common cause of chronic diarrhea
*Diarrhea is common (21 to 57%)
** Others include [[Cryptosporidium parvum]], [[CMV]], [[Salmonella species]], [[Clostridium difficile]], and [[Campylobacter jejuni]]
**[[Giardia lamblia]] is the most common cause of chronic diarrhea
* Can also develop [[sarcoidosis]] (8 to 22%), with granulomatous changes occurring years before the hypogammaglobulinemia
**Others include [[Cryptosporidium parvum]], [[CMV]], [[Salmonella]], [[Clostridium difficile]], and [[Campylobacter jejuni]]
** Mainly in lung, lymph nodes, or liver
*Can also develop [[sarcoidosis]] (8 to 22%), with granulomatous changes occurring years before the hypogammaglobulinemia
** Portends a higher risk of [[immune-mediated thrombocytopenia]] and [[autoimmune hemolytic anemia]]
**Mainly in lung, lymph nodes, or liver
* Autoimmune phenomena include [[immune-mediated thrombocytopenia]], [[autoimmune hemolytic anemia]], [[Evans syndrome]], and [[autoimmune neutropenia]]
**Portends a higher risk of [[immune-mediated thrombocytopenia]] and [[autoimmune hemolytic anemia]]
* Higher rates of malignancies, primarily [[non-Hodgkin lymphoma]] and [[stomach cancer]]
*Autoimmune phenomena include [[immune-mediated thrombocytopenia]], [[autoimmune hemolytic anemia]], [[Evans syndrome]], and [[autoimmune neutropenia]]
** The latter may be related to infection with [[Helicobacter pylori]]
*Higher rates of malignancies, primarily [[non-Hodgkin lymphoma]] and [[stomach cancer]]
**The latter may be related to infection with [[Helicobacter pylori]]


=== Prognosis ===
===Prognosis===


* Decreased life expectancy
*Decreased life expectancy
* Median survival 13.7 years with granulomatous changes or 28.8 years without
*Median survival 13.7 years with granulomatous changes or 28.8 years without


== Investigations ==
==Investigations==
{| class="wikitable"
{| class="wikitable"
!Serum IgG (mg/dL)
!Serum IgG (mg/dL)
Line 61: Line 59:
|}
|}


== Management ==
== Differential Diagnosis ==
*Primary hypogammaglobulinemia
** IgG subclass deficiency
**Hyperimmunoglobulin M syndrome
**Other combined immunodeficiency
*Secondary hypogammaglobulinemia
**Drugs, including [[rituximab]], [[CAR-T]], [[BiTE]], long-term [[corticosteroids]], certain antiseizure medications, cytotoxic chemotherapy
**Malignancy, including [[CLL]], [[lymphoma]], [[multiple myeloma]], and [[Waldenström macroglobulinemia]]
**Thymoma with hypogammaglobulinemia ([[Good syndrome]])
==Diagnosis==
*Over the age of 4 years
* All of the following:
**Low IgA and/or IgM
**Poor or absent response to immunization
** Absence of other immunodeficiency
==Management==


=== Immune Globulin Replacement ===
===Immune Globulin Replacement===


* The mainstay of therapy if IVIg 400 to 600 mg/kg IV monthly, usually given every 3 to 4 weeks
*The mainstay of therapy if IVIg 400 to 600 mg/kg IV monthly, usually given every 3 to 4 weeks
** Can be given subcutaneously, divided every 1 to 2 weeks, if IV access is difficult
**Can be given subcutaneously, divided every 1 to 2 weeks, if IV access is difficult
* Target trough depends on baseline IgG level
*Target trough depends on baseline IgG level
** <100 mg/dL: target trough 600 mg/dL
**<100 mg/dL: target trough 600 mg/dL
** 300 mg/dl: target trough 900 mg/dL
**300 mg/dl: target trough 900 mg/dL
* Although many are IgA deficient, there are low rates of anti-IgA antibodies in CVID, so IVIg is generally safe
*Although many are IgA deficient, there are low rates of anti-IgA antibodies in CVID, so IVIg is generally safe


=== Follow-Up ===
===Follow-Up===
{| class="wikitable"
{| class="wikitable"
!Patients
!Patients
Line 110: Line 123:
|}
|}


== Further Reading ==
==Further Reading==


* How I treat common variable immune deficiency. ''Blood''. 2010;116(1):7-15. doi: [https://doi.org/10.1182/blood-2010-01-254417 10.1182/blood-2010-01-254417]
*How I treat common variable immune deficiency. ''Blood''. 2010;116(1):7-15. doi: [https://doi.org/10.1182/blood-2010-01-254417 10.1182/blood-2010-01-254417]

Latest revision as of 20:31, 6 October 2025

Background

  • Characterized by decreased IgG immunoglobulins, with or without decreases in IgA and IgM, and decreased response to vaccination
  • Must exclude other causes of hypogammaglobulinemia

Epidemiology

  • Affects up to 1 in 25,000 people

Clinical Manifestations

Prognosis

  • Decreased life expectancy
  • Median survival 13.7 years with granulomatous changes or 28.8 years without

Investigations

Serum IgG (mg/dL) Recommendation
<150 repeat immunoglobulins to confirm
150-250 repeat immunoglobulins to confirm

consider tetanus and diphtheria titres

consider pneumococcal vaccine titres pre- and post-vaccination

250-450 repeat immunoglobulins to confirm

check tetanus and diphtheria titres

check pneumococcal vaccine titres pre- and post-vaccination

450-600 repeat immunoglobulins to confirm

check tetanus, diphtheria, MMR, and VZV titres

check pneumococcal vaccine titres pre- and post-vaccination

Differential Diagnosis

Diagnosis

  • Over the age of 4 years
  • All of the following:
    • Low IgA and/or IgM
    • Poor or absent response to immunization
    • Absence of other immunodeficiency

Management

Immune Globulin Replacement

  • The mainstay of therapy if IVIg 400 to 600 mg/kg IV monthly, usually given every 3 to 4 weeks
    • Can be given subcutaneously, divided every 1 to 2 weeks, if IV access is difficult
  • Target trough depends on baseline IgG level
    • <100 mg/dL: target trough 600 mg/dL
    • 300 mg/dl: target trough 900 mg/dL
  • Although many are IgA deficient, there are low rates of anti-IgA antibodies in CVID, so IVIg is generally safe

Follow-Up

Patients Assessment Interval
all History and physical annually
CBC, liver and renal panel, albumin annually
spirometry annually
serum trough IgG ± IgA and IgM 6-12 months
chest x-ray on referral
lung disease high-resolution CT chest 3-4 years or after change of therapy
lung function with DLCO annually
GI complications upper and/or lower endoscopy as required
malabsorption or loss of height bone density and micronutrient assessment as required

Further Reading